Journal of the Chinese Medical Association

Papers
(The H4-Index of Journal of the Chinese Medical Association is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Clinical manifestation and disease progression in COVID-19 infection115
ChatGPT and other artificial intelligence applications speed up scientific writing79
New COVID-19 saliva-based test: How good is it compared with the current nasopharyngeal or throat swab test?44
Classification and citation analysis of the 100 top-cited articles on adult spinal deformity since 2011: A bibliometric analysis35
ChatGPT failed Taiwan’s Family Medicine Board Exam34
Performance of ChatGPT on the pharmacist licensing examination in Taiwan32
Immunology and ovarian cancers28
Comparing paclitaxel-platinum with ifosfamide-platinum as the front-line chemotherapy for patients with advanced-stage uterine carcinosarcoma26
Cardiovascular manifestation and treatment in COVID-1924
Deep learning for abdominal ultrasound: A computer-aided diagnostic system for the severity of fatty liver24
Genomic variance of Open Reading Frames (ORFs) and Spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)24
The impact of COVID-19 in pregnancy: Part II. Vaccination to pregnant women22
Care for patients with musculoskeletal pain during the COVID-19 pandemic: Physical therapy and rehabilitation suggestions for pain management22
Exercise, nutrition, and medication considerations in the light of the COVID pandemic, with specific focus on geriatric population: A literature review21
The impact of COVID-19 in pregnancy: Part I. Clinical presentations and untoward outcomes of pregnant women with COVID-1921
The role of micronutrient and immunomodulation effect in the vaccine era of COVID-1918
Animal models of dry eye: Their strengths and limitations for studying human dry eye disease18
To do one and to get more: Part I. Diabetes and bone17
Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer17
Organ- or function-preservation surgery is recommended, but who is a candidate?17
0.070060968399048